NCT05691881招募中早期 1 期
68Ga-labeled NY105 PET Imaging in Patients
Affiliated Hospital of Jiangnan University1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2022年9月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Evaluation of tissue distribution of 68Ga-NY105
研究概览
简要总结
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY105 PET Imaging in patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients voluntarily signed informed consent;
- •Age 18-75, male or female;
- •Patients diagnosed with cancer confirmed by histopathology or cytology;
- •At least one measurable solid lesion has been examined according RECIST1.1 standard;
- •ECOG score 0~3.
排除标准
- •Recovery from major trauma (including surgery) within 4 weeks prior to study treatment;
- •Patients with systemic or locally severe infections, or other serious coexisting diseases;
- •Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines;
- •Patients with autoimmune diseases, including rheumatoid arthritis;
- •Inadequate control of arrhythmias, including atrial fibrillation;
- •Uncontrolled hypertension;
- •Patients with allergies or allergies to any component of the imaging agent or antibody;
- •Patients who cannot undergo PET/CT imaging scan;
- •Syphilis, HBV, HCV, or HIV positive subjects;
- •Male and female subjects of reproductive age cannot take effective contraceptive measures;
- •Pregnant or lactating women;
- •Patients with a history of mental illness or related conditions;
- •Other subjects considered unsuitable by researchers.
研究组 & 干预措施
68Ga-NY105
Experimental
干预措施: 68Ga-NY105 (Drug)
结局指标
主要结局
Evaluation of tissue distribution of 68Ga-NY105
时间窗: 1 day
Biodistribution of 68Ga-NY105 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 68Ga-PET scans will be reported.
次要结局
未报告次要终点
研究者
Chunjing Yu
Director
Affiliated Hospital of Jiangnan University
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
68Ga-labeled NY104 PET Imaging in PatientsRenal Cell CarcinomaNCT05638256Affiliated Hospital of Jiangnan University10
招募中
早期 1 期
68Ga-labeled NY108 PET Imaging in PatientsProstatic CancerNCT05623878Affiliated Hospital of Jiangnan University100
招募中
早期 1 期
89Zr-labeled NY008 PET Imaging in PatientsMultiple MyelomaNCT05655676Affiliated Hospital of Jiangnan University10
招募中
早期 1 期
177Lu-labeled NY108 SPECT Imaging in PatientsProstate CancerNCT05815394Affiliated Hospital of Jiangnan University10
终止
1 期
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerProstate CancerNCT02483884Life Molecular Imaging SA30